共 167 条
[1]
Baldi I(2018)Epidemiology of meningiomas Neurochirurgie 64 5-14
[2]
Engelhardt J(2010)Epidemiology and etiology of meningioma J Neurooncol 99 307-314
[3]
Bonnet C(2016)Checkpoint inhibition in meningiomas Immunotherapy 8 721-731
[4]
Bauchet L(2014)Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review Neuro Oncol 16 829-840
[5]
Berteaud E(2020)Basis for immunotherapy for treatment of meningiomas Front Neurol 11 945-1009
[6]
Grüber A(2019)Systemic and local immunosuppression in patients with high-grade meningiomas Cancer Immunol Immunother 68 999-552
[7]
Loiseau H(2016)Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma J Neurooncol 130 543-53
[8]
Wiemels J(2017)Regression of intracranial meningioma following treatment with nivolumab: case report and review of the literature J Clin Neurosci 37 51-36
[9]
Wrensch M(2019)Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group Neuro Oncol 21 26-1026
[10]
Claus EB(2019)A phase I/II study of nivolumab plus or minus ipilimumab in combination with multi-fraction stereotactic radiosurgery for recurrent high-grade radiation-relapsed meningioma J Clin Oncol 376 1015-1867